Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health todayExpanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today

Mira Precision Health, Based in Mason, Ohio, Announces U.S. Launch of ToxNav® Advantage™ at the 2026 ASCO® GI Cancers Symposium

Expanded pharmacogenomic panel enhances safety for patients receiving 5-FU and capecitabine

MASON, Ohio, Jan. 5, 2026 /PRNewswire/ — Mira Precision Health today announced the official U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay designed to identify cancer patients at increased risk of severe or potentially life-threatening toxicities from fluoropyrimidine-based chemotherapies, including 5-fluorouracil (5-FU) and capecitabine (XELODA®).

This launch comes amid heightened concern regarding fluoropyrimidine safety in certain patient populations. The U.S. Food and Drug Administration recently updated the XELODA® (capecitabine) prescribing information to include a Black Box Warning highlighting the risk of severe, life-threatening, and potentially fatal toxicities in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. This warning underscores the urgent need for proactive identification of genetically at-risk patients prior to initiating treatment with fluoropyrimidines.

Key features of ToxNav® Advantage™ include:

  • Comprehensive analysis of 23 DPYD gene variants
  • Inclusion of DGLUCY and ENOSF1/TYMS variants predictive of fluoropyrimidine-associated cardiotoxicity (CTRCD) and Hand-Foot Syndrome (HFS)
  • Rapid 48-hour turnaround time for clinically actionable results
  • Clear, clinician-friendly reports that support dose optimization, reduced hospitalizations, and lower treatment-related mortality

The launch will be highlighted by a Mira-sponsored Industry Expert Theater (IET) session at the 2026 ASCO® Gastrointestinal Cancers Symposium in San Francisco, CA.

The 45-minute session, titled “From Oxford to the U.S.: The Clinical Utility Evolution of ToxNav® Advantage™ in Preventing 5-FU/Capecitabine Toxicities,” will be presented by Abdul Rahman Jazieh, MD, MPH, Chief Medical Officer of Mira Precision Health. Dr. Jazieh will discuss a real-world case study of fluoropyrimidine-induced cardiovascular toxicity demonstrating the clinical value of variant testing in identifying at-risk patients and informing care decisions.

Professor David Kerr, CBE, MA, MSc, MD, PhD, DSc, FRCP, founder of the original ToxNav® program, internationally recognized oncology researcher, and Chair of Mira Precision Health’s Scientific Advisory Board, will also be onsite throughout ASCO-GI. As the architect of ToxNav’s scientific foundation and a global leader in fluoropyrimidine toxicity research, Professor Kerr will support the U.S. debut of ToxNav® Advantage™ and be available for expert discussions with clinicians, researchers, and industry stakeholders.

ToxNav® Advantage™ builds on more than a decade of peer-reviewed clinical research and real-world implementation of ToxNav® across U.K. and E.U. healthcare systems. The test analyzes 26 clinically relevant gene variants, including 23 DPYD variants aligned with the Association for Molecular Pathology (AMP) 2025 Tier 1 and Tier 2 classifications, along with additional Oxford-validated markers. ToxNav® Advantage™ uniquely extends fluoropyrimidine toxicity risk assessment beyond DPYD deficiency by incorporating genetic variants associated with cancer therapy–related cardiac dysfunction (CTRCD)—a potentially life-threatening complication—and Hand-Foot Syndrome (HFS), a frequent cause of treatment modification or discontinuation in patients receiving fluoropyrimidines.

“We developed ToxNav® to identify patients with a high likelihood of severe toxicity from 5-FU and capecitabine—two of the most widely prescribed cancer therapies worldwide,” said Professor Kerr. “Through our collaboration with Mira Precision Health, ToxNav® has been optimized for the U.S. market, delivering greater clinical utility and rapid turnaround times that can meaningfully improve patient outcomes.”

“ToxNav® Advantage™ provides oncologists with fast, actionable insights to help prevent life-threatening toxicities before treatment begins,” said Dr. Jazieh. “Our mission is to enable precision-driven care that protects patients across every stage of therapy.”

“As a long-time partner of Mira and strong advocate for life science advancement, we’re excited to see this partnership with Oxford bring life-changing technology to the U.S.,” said Michele Blair, Director of Economic Development for the City of Mason. “We’re leaning in to our ‘Mason Living Lab’ platform, which engages city residents and employees as participants to advance new technology. This program differentiates Mason’s position in the Midwestern ecosystem and accelerates science discovery.”

About Mira Precision Health

Mira Precision Health is a CLIA-certified, high-complexity clinical laboratory headquartered in Mason, Ohio, specializing in precision medicine diagnostics. Through its advanced pharmacogenomic and oncology testing solutions, Mira empowers clinicians nationwide to deliver safer, more personalized cancer care.

About the City of Mason, Ohio

The City of Mason, Ohio, is an established hub for biohealth and biotech life science companies, with focus areas in cardiology, mental health and precision medicine. Mason was one of the first cities in Ohio designated a Premier Life Science Ready Community in 2025 by the Ohio Life Sciences Association for its infrastructure readiness, dedicated support systems, accessible real estate and high-quality resources that make it attractive to life science development. For more information about the City of Mason, visit www.whymason.com or www.imaginemason.org.

For media inquiries, please contact:
Lori Borchers
Vice President, Sales and Marketing
Mira Precision Health
Email: [email protected]
Website: https://www.miraprecision.com/toxnav/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mira-precision-health-based-in-mason-ohio-announces-us-launch-of-toxnav-advantage-at-the-2026-asco-gi-cancers-symposium-302652722.html

SOURCE City of Mason

Market Opportunity
Mira Logo
Mira Price(MIRA)
$0.1182
$0.1182$0.1182
-2.39%
USD
Mira (MIRA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Wealthfront Corporation (WLTH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Wealthfront Corporation (WLTH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of Wealthfront Corporation (“Wealthfront” or the “Company”) (NASDAQ
Share
AI Journal2026/01/21 05:30
IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge!

The post IP Hits $11.75, HYPE Climbs to $55, BlockDAG Surpasses Both with $407M Presale Surge! appeared on BitcoinEthereumNews.com. Crypto News 17 September 2025 | 18:00 Discover why BlockDAG’s upcoming Awakening Testnet launch makes it the best crypto to buy today as Story (IP) price jumps to $11.75 and Hyperliquid hits new highs. Recent crypto market numbers show strength but also some limits. The Story (IP) price jump has been sharp, fueled by big buybacks and speculation, yet critics point out that revenue still lags far behind its valuation. The Hyperliquid (HYPE) price looks solid around the mid-$50s after a new all-time high, but questions remain about sustainability once the hype around USDH proposals cools down. So the obvious question is: why chase coins that are either stretched thin or at risk of retracing when you could back a network that’s already proving itself on the ground? That’s where BlockDAG comes in. While other chains are stuck dealing with validator congestion or outages, BlockDAG’s upcoming Awakening Testnet will be stress-testing its EVM-compatible smart chain with real miners before listing. For anyone looking for the best crypto coin to buy, the choice between waiting on fixes or joining live progress feels like an easy one. BlockDAG: Smart Chain Running Before Launch Ethereum continues to wrestle with gas congestion, and Solana is still known for network freezes, yet BlockDAG is already showing a different picture. Its upcoming Awakening Testnet, set to launch on September 25, isn’t just a demo; it’s a live rollout where the chain’s base protocols are being stress-tested with miners connected globally. EVM compatibility is active, account abstraction is built in, and tools like updated vesting contracts and Stratum integration are already functional. Instead of waiting for fixes like other networks, BlockDAG is proving its infrastructure in real time. What makes this even more important is that the technology is operational before the coin even hits exchanges. That…
Share
BitcoinEthereumNews2025/09/18 00:32
VIRGINIA BEACH’S LANDSTOWN COMMONS ACQUIRED FOR $102 MILLION BY AN AFFILIATE OF YALE REALTY SERVICES CORP.

VIRGINIA BEACH’S LANDSTOWN COMMONS ACQUIRED FOR $102 MILLION BY AN AFFILIATE OF YALE REALTY SERVICES CORP.

First-in-Class Retail Plaza, Located in Prime Area Appeals with Demographic Diversity, High Employment Rate, Military and Vacation Population WHITE PLAINS, N.Y.,
Share
AI Journal2026/01/21 05:28